New Zealand Government Reverses Groundbreaking Anti-Smoking Legislation for Economic Reasons

Regulations by 2FIRSTS.ai
Nov.29.2023
New Zealand Government Reverses Groundbreaking Anti-Smoking Legislation for Economic Reasons
New Zealand's landmark smoking ban law, aimed at achieving a "smoke-free generation," has been repealed by the new government.

According to a report by Hipertextual, former New Zealand Prime Minister Jacinda Ardern announced a groundbreaking tobacco control law in 2021, with the aim of achieving a "smoke-free generation" and saving thousands of lives. The law received widespread support from health legislators around the world, with several countries announcing plans to follow suit. However, the new government in New Zealand repealed the law before it could be enacted, and openly admitted that the decision was driven by economic interests.

 

New Zealand's smoking ban bill aims to achieve its goals by gradually increasing the legal smoking age. Currently, in New Zealand and many other countries, the legal age for smoking is 18. The initial plan is to raise the age to 19 by 2026, followed by an annual increase of one year thereafter. Eventually, teenagers will no longer be permitted to smoke. Despite potentially appearing strict, this regulation is expected to save millions of lives and cost millions of dollars in healthcare expenses.

 

However, in the election, the newly elected government in New Zealand has promised to implement a historic tax reduction, which requires a complete overhaul. Given that the tobacco industry brings in a significant amount of revenue for the government, the newly elected right-wing coalition government wasted no time in making this decision.

 

Newly-appointed Minister of Finance, Nicola Willis, has announced the repeal of the smoking ban bill. This decision, driven by economic factors, did not originate from the Health Ministry. The tobacco industry contributes approximately $2 billion in tax revenue to the New Zealand government annually, making it an effective avenue for offsetting tax deductions.

 

A recent study suggests that Ardern's smoking ban bill could save $1.3 billion in healthcare costs over the next 20 years. However, this does not offset the profits from tobacco sales, thus making it an insufficiently compelling reason for the new government.

 

Furthermore, the World Health Organization (WHO) stated in its tobacco report that approximately 8 million people die each year globally due to smoking-related causes. Out of this number, 7 million people die directly from smoking, while the remaining 1 million are second-hand smoke inhalers. These individuals do not willingly smoke, yet they tragically lose their lives due to exposure to cigarette smoke.

 

Achieving a smoke-free generation is just one of the many proposed measures by the World Health Organization to prevent health issues caused by tobacco. Other measures include conducting health promotion campaigns to assist people in quitting smoking, issuing graphic health warnings, increasing taxes on tobacco companies, and regulating nicotine-containing products such as e-cigarettes.

 

At the beginning of this year, the Director-General of the organization, Tedros Adhanom Ghebreyesus, stated that only four countries in the world have implemented a comprehensive set of measures following most of the organization's recommendations. These countries include Brazil, Mauritius, Turkey, and the Netherlands. Among the member states of the European Union, only the Netherlands has achieved this feat. However, data shows that approximately 18.4% of the population aged 15 and above reported being daily smokers in 2019. The highest smoking rate was recorded in Bulgaria at 28.7%, while Sweden had the lowest at 6.4%.

 

Fortunately, several countries, such as Portugal, have started implementing the smoking ban law repealed by New Zealand and have also set goals to achieve a smoke-free generation.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Australia’s TGA Places Nicotine Pouches Under Therapeutic Goods Rules From July 24, Blocking Imports of Unapproved Products
Australia’s TGA Places Nicotine Pouches Under Therapeutic Goods Rules From July 24, Blocking Imports of Unapproved Products
Australia is strengthening controls on nicotine pouches under its existing therapeutic goods regulatory framework. According to the Therapeutic Goods Administration (TGA), nicotine pouch products must meet regulatory requirements, and unapproved products cannot be legally imported. The move follows Australia’s broader approach of maintaining strict oversight of nicotine products, including nicotine-containing vapes. As nicotine pouches expand globally, Australia’s regulatory approach highlights growing differences in how countries manage emerging smoke-free nicotine products.
Regulations
Jul.27
IQOS Enters Kantar BrandZ Global Top 100 for First Time, Valued at $36.6 Billion and Ranked No. 74
IQOS Enters Kantar BrandZ Global Top 100 for First Time, Valued at $36.6 Billion and Ranked No. 74
Philip Morris International’s IQOS has entered the Kantar BrandZ Top 100 Most Valuable Global Brands for the first time, ranking No. 74 with a brand value of $36.634 billion and becoming one of only three newcomers to the 2026 ranking. Kantar said the combined value of the Global Top 100 reached $13.1 trillion, up 22% year on year, while the threshold for entry rose to a record high. PMI says IQOS has more than 35 million users worldwide and surpassed $10 billion in annual net revenues within a decade of launch.
Sep.03
JTI Research Finds 31% of UK Respondents Offered Illicit Tobacco, While 63% of Ennis Packs Lack Duty Marks
JTI Research Finds 31% of UK Respondents Offered Illicit Tobacco, While 63% of Ennis Packs Lack Duty Marks
Multiple JTI-backed studies in the UK and Ireland indicate that illicit tobacco remains visible across consumer interactions and local markets. In the UK, JTI research found that 31% of respondents said they had been offered illicit tobacco products. In Ireland’s Ennis area, a JTI-commissioned empty pack survey found that 63% of sampled cigarette packs did not carry Irish duty-paid markings. The findings come from industry research rather than official government estimates of illicit tobacco market size, but highlight continued concerns among regulators, legitimate retailers and tobacco companies over illicit trade.
Aug.19
China Tobacco Hubei explores staged nicotine pouch delivery, using dynamic membranes to slow early release and gradient particles to sustain later delivery
China Tobacco Hubei explores staged nicotine pouch delivery, using dynamic membranes to slow early release and gradient particles to sustain later delivery
China Tobacco Hubei Industrial Co., Ltd. disclosed several oral nicotine-related patent applications in August 2026, including two that approach staged nicotine release from different directions. One uses a high-viscosity membrane that forms inside the pouch after contact with saliva to slow rapid early release, while the other uses gradient particles with a faster-disintegrating outer layer and a slower core to create a fast-to-sustained release profile. Together, the filings explore how nicotine pouches could balance initial delivery with release later in use.
Sep.03
BAT Regional Director Fred Monteiro Supports Spain’s Nicotine Rules but Opposes 0.99mg Nicotine Pouch Limit
BAT Regional Director Fred Monteiro Supports Spain’s Nicotine Rules but Opposes 0.99mg Nicotine Pouch Limit
Spanish newspaper El Confidencial interviewed Fred Monteiro, Regional Director for Americas and Europe at British American Tobacco (BAT). Monteiro said BAT supports setting regulatory limits for nicotine products but opposes Spain’s proposed 0.99mg nicotine-per-pouch limit, arguing that such a restriction could affect adult smokers’ transition to alternatives. He said nicotine regulation should be based on scientific evidence and harm reduction principles. Monteiro also said smoke-free products now account for around 25% of BAT’s Americas and Europe business and nearly 30% of its Europe business
BAT
Jul.30
China Discloses First Criminal Case Over Counterfeit Vapes Disguised as “Medical Nebulizers” and “Zero-Nicotine” Products
China Discloses First Criminal Case Over Counterfeit Vapes Disguised as “Medical Nebulizers” and “Zero-Nicotine” Products
Chinese authorities have disclosed the country’s first reported criminal case involving counterfeit vapes marketed as “medical nebulizers” and “zero-nicotine” products. Authorities determined that the products involved were counterfeit vapes and pursued criminal charges for producing and selling counterfeit goods. According to the report, the case resulted in the seizure of 347,000 counterfeit vape pods and 53,700 vape devices, with physical goods valued at 22.13 million yuan.
Aug.04